Abstract Number: 1415 • 2017 ACR/ARHP Annual Meeting
TNF-Induced IRF1 Is Critical for the Inflammatory Gene Expression in Fibroblast-like Synoviocytes
Background/Purpose: Fibroblast-like synoviocytes (FLS) are increasingly recognised as major pathogenic cells in synovial inflammation of patients with Rheumatoid Arthritis (RA). In response to pro-inflammatory stimuli,…Abstract Number: 1428 • 2017 ACR/ARHP Annual Meeting
Discovery and Characterization of JNJ-61178104, a Bispecific Antibody Against Human Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL)-17A
Background/Purpose: Tumor necrosis factor alpha (TNFa) and interleukin (IL)-17A are pleiotropic cytokines implicated in the pathogenesis of several autoimmune diseases including Rheumatoid Arthritis (RA) and…Abstract Number: 1433 • 2017 ACR/ARHP Annual Meeting
Tailoring Second-Line Biologic Therapy in Rheumatoid Arthritis: New Findings on the Usefulness of Antibody Status to Optimise Drug Selection
Background/Purpose: Treatment of rheumatoid arthritis (RA) has been revolutionized by the introduction of Tumour Necrosis Factor alpha inhibitors (TNFi). However a significant proportion of patients…Abstract Number: 1791 • 2017 ACR/ARHP Annual Meeting
TET1 Is an Important Transcriptional Activator of the Tnfa Locus in Macrophages
Background/Purpose: Activated macrophages are found in the inflamed and hyperplastic synovial RA tissue. Macrophages are the main producers of high levels of pro-inflammatory cytokines such…Abstract Number: 1817 • 2017 ACR/ARHP Annual Meeting
Abatacept Shows Better Sustainability Than TNF Inhibitors When Used Following Initial Biologic DMARD Failure in the Treatment of RA: 8 Years of Real-World Observations from the Rhumadata® Clinical Database and Registry
Background/Purpose: In the absence of biomarkers predicting response to a specific therapy, the choice of second biologic is based mostly on habit and availability of…Abstract Number: 1942 • 2017 ACR/ARHP Annual Meeting
CTLA4-Ig Directly Inhibits Osteoclast Generation from Human Peripheral Monocytes and Tumor Necrosis Factor α-Treated Inflammatory Monocytes
Background/Purpose: CTLA-4 is a surface protein on T lymphocytes, which negatively regulates the co-stimulation process between antigen-presenting cells and T cells. CTLA-4 binds to monocytes…Abstract Number: 2024 • 2017 ACR/ARHP Annual Meeting
Prediction of Response to Certolizumab-Pegol in Rheumatoid Arthritis By Functional MRI of the Brain – an Interim Analysis of an Ongoing Investigator Initiated Phase III Trial
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) signify a major advance in the treatment of rheumatoid arthritis (RA). However, treatment success initially remains uncertain as one…Abstract Number: 2448 • 2017 ACR/ARHP Annual Meeting
Increased Cumulative Exposure to Tumor Necrosis Factor Inhibitors Reduces Radiographic Progression in US Veterans with Rheumatoid Arthritis in Real World Clinical Practice
Background/Purpose: While tumor necrosis factor inhibitors (TNFi) have been proven to reduce progression of structural joint damage in rheumatoid arthritis (RA) in randomized clinical…Abstract Number: 2450 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Abatacept Versus TNFi in Patients with RA Who Are CCP+ in the United States Corrona Registry
Background/Purpose: Anti-cyclic citrullinated peptide positivity (CCP+) is associated with a better response to abatacept than anti-CCP negativity in patients with RA1,2; however, there are no…Abstract Number: 2485 • 2017 ACR/ARHP Annual Meeting
Outcomes of Switching from TNF Inhibitors to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
Background/Purpose: Tumor necrosis factor alpha (TNFα) inhibitors have been used to treat rheumatoid arthritis (RA) for >10 years. The outcomes has revolutionized the treatment goal…Abstract Number: 75 • 2017 ACR/ARHP Annual Meeting
Factors Associated with TNF Receptor 2 Levels Above the Measurable Range in Rheumatoid Arthritis
Background/Purpose: Tumor necrosis factor-alpha (TNFa) is involved in the pathogenesis of RA and is increasingly being studied as a biomarker of cardiovascular disease (CVD). While…Abstract Number: 2711 • 2017 ACR/ARHP Annual Meeting
Mucosal-Associated Invariant T Cells Are an Important Source of TNF in Rheumatoid Arthritis
Background/Purpose: CD8+ T cells have been described to comprise up to 40% of the rheumatoid arthritis (RA) synovial T cell compartment but their pathogenic function…Abstract Number: 495 • 2016 ACR/ARHP Annual Meeting
The Relative Performance of 28-Joint Disease Activity Score Based on C-Reactive Protein with Three Versus Four Components in Patients with Rheumatoid Arthritis
Background/Purpose: The commonly used version of the 28-joint disease activity score based on C-reactive protein (DAS28-CRP4) includes swollen and tender joint counts (S/TJC), CRP and…Abstract Number: 598 • 2016 ACR/ARHP Annual Meeting
An Assessment of the Correlation Between Gender and Anticipated Drug Retention to TNF Inhibitors: A Meta-Regression Analysis
Background/Purpose: It is generally believed that a wide variety of patient-specific factors, and in particular gender, are likely to influence the response and tolerability of…Abstract Number: 628 • 2016 ACR/ARHP Annual Meeting
Analysis of Baseline Characteristics of Rheumatoid Arthritis Patients Treated with Abatacept Compared to Those Treated with Tumor Necrosis Factor Inhibitors in Clinical Practice
Background/Purpose: Currently, the most widely used biological agents for rheumatoid arthritis (RA) patients are the inhibitors of the tumor necrosis factor (TNFi), although other biological…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 6
- Next Page »